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How dramatically things have changed in 10 years! In
1988, we described a colon cancer–prone family with a
tendency to form small, right-sided adenomas (Lynch et
al. 1988). We proposed that the family represented either
hereditary nonpolyposis colorectal cancer with a pre-
viously undescribed precursor lesion or a new colon can-
cer syndrome. (We were wrong on both counts.) Later,
emphasizing the morphology of the small adenomas, we
proposed the term hereditary flat adenoma syndrome
(another wrong idea) (Lynch et al. 1992). Investigators
from the University of Utah made the critical link to the
APC gene, recognized that mutations nearer the 5′ end
of the gene were associated with the phenotype, and
supplied the appropriate name: attenuated familial ad-
enomatous polyposis (AFAP) (Spirio et al. 1992, 1993).
Now, Soravia et al. 1998 (in this issue) add new evidence
for genotype-phenotype correlations and extend the mu-
tational spectrum associated with the attenuated
phenotype.
Soravia et al. (1998) describe three classes of APC
mutations in kindreds with an attenuated phenotype.
First, there are four families with mutations in exon 4
that generate truncated proteins prematurely terminated
at nucleotides 551 (three families) or 487. Individuals
with these mutations tend to form dozens to hundreds
of adenomas, but the range is broad (2 to 1500), and
in some patients the adenoma phenotype resembles that
of “classic” familial adenomatous polyposis (FAP). (This
is similiar to our experiences with these types of fami-
lies.) Upper gastrointestinal manifestations are common,
again paralleling our experience. Second, there are two
families with truncating mutations in exon 9, one re-
sulting in premature termination at nucleotide 994 and
one at nucleotide 1014. Individuals with these mutations
have fewer adenomas (1–150) and no apparent upper
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gastrointestinal manifestations. Finally, there is a re-
markable family with a mutation near the distal end of
the APC gene, resulting in termination at nucleotide
6218. The four family members known to carry this
mutation have manifested as many as 36 adenomas; two
have adenomas in the upper gastrointestinal tract, and
none of the four has developed a colorectal carcinoma
(CRC). This family might best be classified as very at-
tenuated FAP, and its paucity of adenomas and apparent
low risk for CRC make one wonder how much the mu-
tation found in this family contributes to apparently spo-
radic CRC in the general population. In all groups, age
at diagnosis was older than for classic FAP, and right-
sided adenoma predominance with rectal sparing was
seen in at least some individuals.
We know now that individuals carrying germ-line mu-
tations of the APC gene might have anywhere from one
to thousands of adenomas and that the lifetime risk for
CRC ranges from low to nearly 100%. The phenotypic
range forms a continuous spectrum, and it is probably
arbitrary to divide the spectrum into profuse polyposis,
classic polyposis, sparse polyposis, attenuated polyposis,
and very attenuated polyposis. How many adenomas
can there be, for example, before attenuated polyposis
becomes sparse polyposis? Arbitrary though the divi-
sions may be, they are also necessary, because estimates
about the lifetime risk for CRC will influence the deci-
sion whether to proceed with prophylactic colectomy
and how colectomy should be performed, and estimates
of the expected incidence and location of extracolonic
manifestations will influence surveillance strategies.
How, then, can we best subclassify FAP? Certainly,
genetic analysis will play a role, given the genotype-
phenotype correlations described above and other work
(reviewed by Soravia et al.) correlating specific muta-
tions with other phenotypic features, such as desmoid
tumors and congenital hypertrophy of retinal pigment
epithelium. Additional descriptive studies correlating
mutations with phenotype will undoubtedly appear, fur-
ther extending our ability to predict clinical findings on
that basis. We doubt, however, that analysis of APC
mutations alone will allow definitive subclassification.
There are just too many phenotypic variations, even
within families carrying identical mutations. The role of
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modifier genes and the effect of environmental influences
remain to be elucidated. A combination of clinical judg-
ment and genetic analysis is called for.
We think there are two important messages to convey:
First, clinicians must be aware of the broad range of
clinical features that FAP can present. AFAP should be
considered when fewer adenomas are present (!100 in
at least some family members) and when they tend to
be right sided. Second, classically described surveillance
and prophylactic measures do not apply to all cases of
FAP. In the management of patients that we classify as
AFAP, we recommend colonoscopy with polypectomy.
When the total number of colonic adenomas is too nu-
merous to follow with colonoscopy and polypectomy,
particularly when the adenomas are located in the ce-
cum, we recommend prophylactic subtotal colectomy
with continued follow-up of the rectal segment by en-
doscopy. We also suggest early upper endoscopy be per-
formed in these families, in that multiple fundic gland
polyps have preceded the finding of pathology in the
colon in the relatively large number of our patients with
AFAP. Although fundic gland polyps commonly occur
in the general population and are considered to be be-
nign, we find them to be a sensitive marker of mutation
carriers in the AFAP setting. There are rare reports of
dysplasia in fundic gland polyps of AFAP patients
(Zwick et al. 1997), something we have observed as well.
These findings may represent gastric dysplasia coinci-
dentally involving a fundic gland polyp, but clearly the
stomach bears watching in AFAP. We should also men-
tion the potential for duodenal adenomas and periam-
pullary cancer, but we emphasize that we do not know
whether the periampullary cancer risk in AFAP ap-
proaches that of classical FAP. We should be on the look-
out for desmoids, although they were not previously
reported in AFAP. Of course, we should continue the
search for any of the extracolonic cancers that charac-
terize the classical form of FAP.
Genotype-phenotype interactions in FAP are complex,
but if a mutation known to be associated with an at-
tenuated phenotype is documented, the clinician must
look for clinical evidence of attenuated phenotype. If
clinical findings support the diagnosis, surveillance and
management guidelines should be modified accordingly.
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